Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer

Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer

Platinum-based chemotherapy remains the cornerstone of treatment for most people with non-small cell lung cancer (NSCLC), either as adjuvant therapy in combination with a second cytotoxic agent or in combination with immunotherapy. Resistance to therapy, either in the form of primary refractory dise...

Full description

Bibliographic Details
Main Authors: Sarah-Louise Ryan, Keyur A. Dave, Sam Beard, Martina Gyimesi, Matthew McTaggart, Katherine B. Sahin, Christopher Molloy, Neha S. Gandhi, Eric Boittier, Connor G. O’Leary, Esha T. Shah, Emma Bolderson, Anne-Marie Baird, Derek J. Richard, Kenneth J. O’Byrne, Mark N. Adams
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
platinum-based chemotherapy
cisplatin
quantitative proteomics
biomarkers
therapeutic targets
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.615967/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.615967/full

Similar Items